REQUEST A DEMO
Total
USD $0.00
Search more companies

Galenika A.D. Beograd (Serbia)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Galenika A.D. Beograd Profile Updated: June 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Galenika, a state-controlled firm established in 1945, was the first company in former Yugoslavia to be acquired by a foreign partner.
ICN Pharmaceuticals, which acquired a 75% stake in the drug maker under a 1990 agreement, planned to use it as a platform for growth in eastern Europe.
Serbia's government took over the Belgrade plant of ICN Pharmaceuticals in February 1999, after the commercial court in Belgrade ruled that ICN held a 35% stake and not 75%. Galenika claimed a 25% share of the Serbian pharmaceuticals market in 2005, producing 36 out of the 100 best selling drugs in the country.
Serbia’s Privatisation Agency opened a privatisation tender for the company in December 2009 but it failed.
In June 2010, Galenika opened a EUR 50 million solid drugs plant in Zemun. A month later, the firm announced plans to open a representative office in Albania. As of 2017, the company is represented in Montenegro, Bosnia i Herzegovina, Russia and Macedonia.

Headquarters
Batajnicki Drum Bb
Belgrade; Belgrade; Postal Code: 11080

Contact Details: Purchase the Galenika A.D. Beograd report to view the information.

Website: http://www.galenika.co.rs

Basic Information
Total Employees:
Purchase the Galenika A.D. Beograd report to view the information.
Outstanding Shares:
Purchase the Galenika A.D. Beograd report to view the information.
Registered Capital:
Purchase the Galenika A.D. Beograd report to view the information.
Financial Auditors:
Purchase the Galenika A.D. Beograd report to view the information.
Incorporation Date:
April 30, 1991
Key Executives
Purchase this report to view the information.
Acting General Director
Subsidiaries
Galenika-klirit
100%
Company Performance
Financial values in the chart are available after Galenika A.D. Beograd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
4.14%
Total operating revenue
16.26%
Operating profit (EBIT)
22.88%
EBITDA
18.32%
Net Profit (Loss) for the Period
5.81%
Total assets
20.81%
Total equity
14.36%
Operating Profit Margin (ROS)
3.35%
Net Profit Margin
0.27%
Return on Equity (ROE)
-1.17%
Debt to Equity Ratio
1.46%
Quick Ratio
-0.11%
Cash Ratio
-0.17%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?